Related Experiment Videos
Neuroblastoma in the neonate
1Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA. john.lukens@mcmail.vanderbilt.edu
Seminars in Perinatology
|September 4, 1999
Summary
Neuroblastoma, a common neonatal cancer, shows variable clinical courses. Understanding its biologic determinants guides treatment, with many tumors regressing spontaneously or responding to surgery alone.
Area of Science:
- Pediatric Oncology
- Cancer Biology
- Clinical Medicine
Background:
- Neuroblastoma is the most frequent pediatric malignancy in neonates.
- It exhibits significant variability in presentation and clinical behavior.
- Understanding biologic determinants is key to predicting neuroblastoma's course.
Purpose of the Study:
- To review the clinical course of neuroblastoma.
- To correlate clinical outcomes with known biologic determinants.
- To inform management strategies based on tumor characteristics.
Main Methods:
- Review of existing literature on neuroblastoma.
- Analysis of clinical presentations and outcomes.
- Correlation of tumor behavior with biological factors.
Main Results:
- Tumors detected via screening often regress or mature with minimal intervention.
- Low-stage neuroblastomas with favorable biology are typically treated with surgery.
- Advanced stages (3, 4, 4S) require multimodal therapy including chemotherapy.
- Stage 4S management depends on tumor biology and organ function impact.
Conclusions:
- Neuroblastoma's clinical trajectory is strongly influenced by its biologic features.
- Tailored treatment strategies, informed by biology, improve patient outcomes.
- Early detection and risk stratification are crucial for effective neuroblastoma management.